anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a Chinese medicine prescription for curing chronic myeloid leukemia and a preparation method thereof, pertaining to the art of Chinese medicine. The internal prescription includes 20 to 40g of radix notoginseng, 10 to 40g of field thistle, 15 to 40g of pilose deer horn, 20 to 45 of lotus powder, 20 to 50g of prepared rehmannia rhizome, 20 to 55g of donkey-hid gelatin, 20 to 60g of dangshen, 20 to 40g of milk veteh, 20 to 40g of carbonized sanguisorba root, 15 to 40g of saffron, 10 to 40g of medlar, 15 to 45g of carbonized buffalo horn, 15 to 50g of Chinese caterpillar fungus, 10 to 40g of carbonized leatherleaf millettia, 10 to 45g of carbonized black plum and 10 to 50g of carbonized hair. The external prescription includes 5 to 15g of carbonized radix notoginseng, 5 to 20g of carbonized setose thistle, 5 to 25 carbonized field thistle, 5 to 15g of carbonized human hair, 5 to 20g of carbonized petiole of windmill palm, 5 to 15g of carbonized rehmannia root and 5 to 25g of common bletilla. The oral powder made by smashing the internal materials is added with honey and made into honey pills or added with water and made into waterdewed pills. The external materials are smashed to obtain the external powder. Patients with chronic myeloid leukemia select honey pill or waterdewed pill and have one pill before three meals a day; the external powder is coated on the affected part by a tampon. Patients with chronic myeloid leukemia use the present invention both for external use and oral administration.
MYRBETRIQ Monotherapy

The recommended starting dosage of MYRBETRIQ is 25 mg orally once daily. If needed, increase to the maximum dosage of MYRBETRIQ 50 mg orally once daily after 4 to 8 weeks. For administration instructions, see Dosage and Administration ( 2.7) . 

MYRBETRIQ Combination Therapy with Solifenacin Succinate

The recommended starting dosage for combination treatment is MYRBETRIQ 25 mg orally once daily and solifenacin succinate 5 mg orally once daily. If needed, increase to the maximum dosage of MYRBETRIQ 50 mg orally once daily after 4 to 8 weeks. Refer to the Prescribing Information for solifenacin succinate for additional information. For administration instructions, see Dosage and Administration ( 2.7) .
Bioreactors are useful for cartilage tissue engineering because traditional batch culture is not optimal for cartilage tissue growth. The present invention attempts to maximize diffusive transport to engineered cartilage constructs by replenishing the culture medium in a continuous flow bioreactor. The medium is supplemented to maintain a pH of 7.0 to 7.6 until the construct reaches a size of at least 1.5 square centimetres. Chondrocytes can be directly cultured from a biopsy without a separate expansion phase. Subject-specific cartilage constructs can be produced from autologous cells. Phenotypically stable, large-sized engineered cartilage constructs that are not hyper-cellularized can be produced. These constructs are desired for articular cartilage repair of damaged joints
### Teratogenic Effects. Pregnancy Category B

Reproduction studies performed with methyldopa at oral doses up to 1000 mg/kg in mice, 200 mg/kg in rabbits and 100 mg/kg in rats revealed no evidence of harm to the fetus. These doses are 16.6 times, 3.3 times and 1.7 times, respectively, the maximum daily human dose when compared on the basis of body weight; 1.4 times, 1.1 times and 0.2 times, respectively, when compared on the basis of body surface area; calculations assume a patient weight of 50 kg. There are, however, no adequate and well-controlled studies in pregnant women in the first trimester of pregnancy. Because animal reproduction studies are not always predictive of human response, methyldopa should be used during pregnancy only if clearly needed.

Published reports of the use of methyldopa during all trimesters indicate that if this drug is used during pregnancy the possibility of fetal harm appears remote. In five studies, three of which were controlled, involving 332 pregnant hypertensive women, treatment with methyldopa was associated with an improved fetal outcome. The majority of these women were in the third trimester when methyldopa therapy was begun.

In one study, women who had begun methyldopa treatment between weeks 16 and 20 of pregnancy gave birth to infants whose average head circumference was reduced by a small amount (34.2 ± 1.7 cm vs. 34.6 ± 1.3 cm [mean ± 1 S.D.]). Long-term follow-up of 195 (97.5%) of the children born to methyldopa-treated pregnant women (including those who began treatment between weeks 16 and 20) failed to uncover any significant adverse effect on the children. At four years of age, the developmental delay commonly seen in children born to hypertensive mothers was less evident in those whose mothers were treated with methyldopa during pregnancy than those whose mothers were untreated. The children of the treated group scored consistently higher than the children of the untreated group on five major indices of intellectual and motor development. At age 7 and one-half developmental scores and intelligence indices showed no significant differences in children of treated or untreated hypertensive women.
Nearly all Parkinson's disease (PD) patients eventually develop abnormal and unwanted movements (dyskinesias; LID) caused by the gold standard treatment, Levodopa. The severity of these movements can range from subtle to extremely debilitating and may or may not interfere with normal activities such as putting on a coat or brushing ones teeth. Current estimates of the prevalence of LID widely range from 12 % to 100% affected after one year. The purpose of this study is to estimate the median onset time of levodopa induced dyskinesia in newly treated Parkinson's disease patients. All participants will complete seven overnight visits at the OCTRI Inpatient unit over 5 years. During the next day, participants will complete a mental task while standing on a force plate for one minute every half hour until the end of the study. A levodopa IV infusion will occur from 0900 to 1100.
AIM: Postoperative gastrointestinal dysfunction (POGD) is a common complication following colorectal surgery. This study aimed to investigate the incidence and risk factors of POGD after minimally invasive surgery and to assess the relationship between robotic surgery, POGD, and their outcomes.
METHOD: Patients who had undergone minimally invasive colorectal surgery at our institution between July 2018 and November 2023 were retrospectively enrolled. POGD was diagnosed based on the presence of two or more intestinal symptoms within 72 h or more after surgery. Risk factors were identified through regression analyses, and the impact of POGD on outcomes was assessed using linear regression.The association between those factors was assessed using subgroup analysis and hierarchical regression.
RESULTS: A total of 226 patients were included in the analysis, including 33 with POGD. POGD occurred in 14.6% of patients, with a lower incidence in robotic surgery (7.3%) than in laparoscopic surgery (19.8%). Multivariate analysis indicated that robotic surgery had a protective effect, while blood loss exceeding 50 ml was an independent risk factor for POGD. POGD was also correlated with longer length of stays and higher costs. The association between POGD, length of stay, and cost varied depending on the surgical platform. Robotic surgery exacerbated the effect of POGD on short-term outcomes, which aligned with the observed significant interaction effect.
CONCLUSION: POGD remains a prevalent postoperative disease. Preventive strategies, including meticulous hemostasis techniques and robotic surgery, should be prioritized by healthcare professionals to reduce POGD risk, improve short-term outcomes, and preserve healthcare resources.
<P>PROBLEM TO BE SOLVED: To obtain a medicine useful for preventing and treating an immunological disease and to provide a method.  <P>SOLUTION: The new gene of an immune function inhibitory molecule participates in modulation of an immune function. The protein is obtained. The method for efficiently evaluating an active modulator against the protein is provided. The new gene (mcd054) of the immune function inhibitory molecule participates in the modulation of the immune function. The protein (MCD054) is encoded by the gene. The recombinant vector contains the DNA. The transformant cell is transformed by the recombinant vector. The method for searching an activity modulation substance of the protein is provided. The antibody has reactivity to the protein or its partial peptide.  <P>COPYRIGHT: (C)2004,JPO
The present invention relates to a novel tumor apoptosis 2 ligand complete gene obtained from Chinese's peripheral blood mononuclear cells, namely an Apo-2L I gene, which relates to the technical field of medical biological engineering. The novel tumor apoptosis 2 ligand complete gene is utilized to prepare human soluble tumor apoptosis protein, namely tumor apoptosis ligand or Apo-2L I 100. Compared with the existing tumor apoptosis 2 ligand complete gene(Apo-2L gene), besides the novel tumor apoptosis 2 ligand complete gene is lack of 42 nucleotides from number 271 to number 313 at the end 5' in the coding region of the existing Apo-2L gene, the rest part is the same as that of the existing Apo-2L gene, specifically, the encoded corresponding amino acids can not be changed even though several nucleotides are different. The encoded protein Apo-2L I is lack of 14 amino acids correspondingly but has the same apoptosis function for tumor cells. The Apo-2L I100 is completely same as the existing human soluble tumor apoptosis protein Apo-2L114. The Apo-2L I gene is used as a template and pBV220 is utilized to construct a prokaryotic expression vector pBV-Apo-2L I100, so that the prepared Apo-2L I100 can directly express biological activity. The preparation method has the advantages of convenience, high yield and high quality.
Participants in the treatment group will come to the University of Wisconsin lab for six weeks to train 3-5 days each week under research staff supervision. Each training session will last 30-60 minutes and will include playing our in-house Ninja Training game combined with balance games from the Wii Fit.
Udenafil (Zydena), a newly developed PDE-5 inhibitor, has been proved to have similar efficacy and safety profile, compared with other PDE-5 inhibitors. Also, laboratory data showed that udenafil inhibits ventricular hypertrophy and fibrosis in rat heart failure model. Based on these results, the investigators hypothesized that udenafil would improve symptom, exercise capacity and hemodynamic status in patients with systolic heart failure. In this 12-week, randomized, double-blind, placebo-controlled trial, patients with systolic heart failure will be enrolled according to the eligibility criteria. After randomization, study participants will be assigned to receive either 50mg of udenafil or placebo two times a day for 4 weeks, and then the dosage will be doubled to 100mg two times a day for next 8 weeks. Participants will attend study visits at baseline and weeks 4 and 12. Physical examination, medical history review, blood sample collection and electrocardiogram will be conducted on each study visits. At baseline and week 12, participants will undergo cardiopulmonary exercise test and exercise echocardiography. At every study visits,researchers will collect health information.
This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination processes for preventing infections in subjects are also provided. The novel processes comprise introducing into or adminstering to a subject one or more antigens, or trained or adopted immune cells. These antigens or immune cells are capable of establishing or increasing at least one first specific immune response and decreasing at least one second specific immune response. Such responses include components, such as cellular immune reaction elements, humoral immune reaction elements and cytokines, the latter also encompassing interferons and lymphokines. Useful compositions are also provided by this invention.
Adequate sleep is crucial for individuals' well-being and cognitive functioning. However, medical students face unique challenges that disrupt their sleep patterns, such as a rigorous curriculum, long study hours, and high-stress levels. Understanding the sleep patterns and quality among medical students in Nigeria is important to develop targeted interventions and support their overall well-being. This study involved 802 medical students from 3 medical schools in Southwest Nigeria. Participants completed an online questionnaire that collected data on their demographic characteristics, sleep patterns and self-reported sleep quality. Descriptive statistics and correlation analysis were used to analyze the data and identify patterns and associations. Most participants were female (56.9%), with the highest representation from the UNILORIN (65.5%). The average reported sleep duration was 5.74 hours per night, indicating insufficient sleep. Irregular bedtimes and wake-up times were commonly reported. A significant proportion of students consumed coffee late at night (27.1%) and used medication to induce sleep (24.3%). Sleep patterns and behaviors, such as snoring (36.1%) and nocturnal eating (57.6%), were reported. Overall, participants reported satisfactory (28.3%) or poor (29.7%) sleep quality. Correlation analysis revealed significant associations between sleep patterns, sleep quality, academic performance, and other sleep-related factors. The study identified insufficient sleep duration, irregular bedtimes, late-night coffee consumption, and poor sleep quality. These findings emphasize the need for interventions and strategies to promote healthy sleep habits among medical students, which can positively impact their overall health and academic performance.
The present invention is directed to genes and gene products related to Min-K which form ion channels and to a process for diagnosis of ion channel disorders, including long QT syndrome (LQT). For example, KCNE2 forms IKr potassium channels and is associated with LQT. LQT is diagnosed in accordance with the present invention by analyzing the DNA sequence of KCNE2 of an individual to be tested and comparing the respective DNA sequence to the known DNA sequence of a normal KCNE2 gene. Alternatively, these MinK-related genes of an individual to be tested can be screened for mutations which cause ion channel disorders, including LQT. Prediction of ion channel disorders, including LQT, will enable practitioners to prevent the disorders using existing medical therapy. This invention is further directed to the discovery that the HERG and KCNE2 (also known as MiRP1) proteins coassemble to form a cardiac IKr potassium channel.
Disclosed herein are compounds of formula (I) or (II). The compounds include an agent (e.g., a pharmaceutical agent, a cosmetic agent, or a nutritional agent) via a linker that includes a boronate ester moiety in the backbone of the linker. The compound may be a monomer. Also provided herein are polymers prepared by polymerizing the monomers. The polymers can be used to deliver the agents to a subject, tissue, biological sample, or cell. Also provided herein are methods of making the polymers, compositions, and kits comprising the polymers, and methods of use involving the polymers or compositions (e.g., for delivering an agent)Treating, preventing, diagnosing diseases). The structure of the boronate moiety can be fine-tuned such that properties associated with delivery to a subject, biological sample, tissue, or cell can be fine-tuned.
The invention provides a traditional Chinese medicine combination. The traditional Chinese medicine combination is prepared by using the following raw materials in parts by weight: 50-150 parts lightyellow sophora root, 20-80 parts of Chinese honeylocust fruit, 20-80 parts of belvedere fruit, 50-100 parts of amur cork-tree, 50-150 parts of white mulberry root bark, 50-150 parts of ephedra root, 50-150 parts of Sichuan chinaberry bark and 50-150 parts of alum. The traditional Chinese medicine combination can be prepared into any commonly and externally used preparation, healthcare product or cosmetic product. The invention further provides a preparation and use of the traditional Chinese medicine combination. The traditional Chinese medicine combination provided by the invention can effectively treat seborrheic dermatitis, has an adjuvant treatment effect to other diseases such as psoriasis, eczema and tinea capitis causing grease secretion abnormality, and has a certain bacteriostatic function. The invention further provides a traditional Chinese medicine lotion consisting of the traditional Chinese medicine combination and base materials. In addition to conventional hair cleaning effect, the traditional Chinese medicine lotion also has the above-mentioned medicine efficacy, is safe to use and has no toxic and side effect.
Methods and systems are provided for displaying the change in size of a CAD identified pattern over time. Patterns on medical images stored in a medical imaging database are identified and measured using a CAD system. A user interface provides users with access to the medical images stored in imaging database via a network. A medical image belonging to a patient historical exam category and having at least one CAD identified pattern is displayed to a user via the user interface. The size of the CAD identified image pattern and the medical exam date associated with the medical image is compiled for each of the medical images belonging to the patient historical exam category. A graphic is then generated showing the sizes of the CAD identified image pattern and the medical exam dates associated with the medical image.
This is a Phase 1, open-label (all people know the identity of the intervention), single-sequence study to evaluate the potential interaction of steady-state telaprevir on the steady-state pharmacokinetics of methadone. The study consists of 3 phases: the screening phase (within 21 days prior to the start of supervised methadone intake on Day -14), treatment phase, and follow-up phase. Participants on stable methadone maintenance therapy will be enrolled in this study and their methadone doses will not be changed starting at Day -14. During the treatment phase, telaprevir will be added for 7 days (from Day 1 to Day 7) to participants' current methadone therapy. The methadone dosage will not to be changed from Day -14 until Day 7. All the intakes of methadone and telaprevir will be supervised and pharmacokinetic parameters will be measured during the study. Safety evaluations for adverse events, clinical laboratory tests, alcohol breath test, cardiovascular safety, and other evaluations (physical examination, and pharmacodynamic assessments) will be performed throughout the study. The total duration of the study for each participant is approximately 60 days.
PROBLEM TO BE SOLVED: To make it possible to suppress color fading and to check a lesion with macroscopy by preparing a tissue marker for marking the excised section in a surgical excision operation and diagnosis without entailing laparotomy and thoracotomy from a dyeing agent and a material which hardly diffuses and has bioadaptability. SOLUTION: This tissue marker is prepd. by mixing the dyeing agent and the material which hardly diffuses and has the bioadaptability. Collagen, gelatin, agarose, fibrinogen-thrombin, polysaccharides-calcium salt, cyanoacrylate and mixtures composed of the materials selected from these groups are used as the material which hardly diffuses and has the bioadaptability. A contrast medium is further mixed at need with such material. Such tissue marker is obtd. by adding and mixing the prescribed amt. of the dyeing agent to and with the soln. or dispersion of the material which hardly diffuses and has the bioadaptability and is injected into the tissues by using a injection needle, etc., by which the tissues are dyed.
In this condition, participants will be asked to sit and watch various documentaries or educational videos on topics NOT related to physical activity. These will last approximately 20 minutes and will occur before each TMS session.
This disclosure provides a composition containing a conjugate with a modified insulin molecule. The conjugate has an insulin molecule, which can be insulin or an insulin analog, glucagon, GLP-1, GLP-2 or a GLP-1 agonist. The conjugate also contains one or more polymers. Each of the one or more polymers is covalently linked to the insulin molecule. Additionally, each of the one or more polymers is covalently linked to between 0 to 50 copies of a decoy ligand, and to between 0 to 50 copies of a glucose-binding agent, such that the combined total number of glucose-binding agents and decoy ligands covalently linked to each of the one or more polymers is at least 1. The conjugate can reversibly bind to soluble glucose and in which the extent of its glucose-binding controls the extent to which the modified insulin is able to bind to and activate the insulin receptor. Methods of making the conjugate, as well as use of the conjugate in treatment, are also provided.
PURPOSE: Delirium is a common and serious comorbidity in patients with advanced cancer, necessitating effective management. Nonetheless, effective drugs for managing agitated delirium in patients with advanced cancer remain unclear in real-world settings. Thus, the present study aimed to explore an effective pharmacotherapy for this condition.
METHODS: We conducted a secondary analysis of a multicenter prospective observational study in Japan. The analysis included patients with advanced cancer who presented with agitated delirium and received pharmacotherapy. Agitation was defined as a score of the Richmond Agitation-Sedation Scale for palliative care (RASS-PAL) of ≥ 1. The outcome was defined as -2 ≤ RASS-PAL ≤ 0 at 72 h after the initiation of pharmacotherapy. Multiple propensity scores were quantified using a multinomial logistic regression model, and adjusted odds ratios (ORs) were calculated for haloperidol, chlorpromazine, olanzapine, quetiapine, and risperidone.
RESULTS: The analysis included 271 patients with agitated delirium, and 87 (32%) showed -2 ≤ RASS-PAL ≤ 0 on day 3. The propensity score-adjusted OR of olanzapine was statistically significant (OR, 2.91; 95% confidence interval, 1.12 to 7.80; P = 0.030).
CONCLUSIONS: The findings suggest that olanzapine may effectively improve delirium agitation in patients with advanced cancer.